BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Colombo GL, Di Matteo S, Antinori A, Medaglia M, Murachelli S, Rizzardini G. Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines. Clinicoecon Outcomes Res 2013;5:489-96. [PMID: 24124383 DOI: 10.2147/CEOR.S48246] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Tran BX, Nguyen LH, Turner HC, Nghiem S, Vu GT, Nguyen CT, Latkin CA, Ho CSH, Ho RCM. Economic evaluation studies in the field of HIV/AIDS: bibliometric analysis on research development and scopes (GAPRESEARCH). BMC Health Serv Res 2019;19:834. [PMID: 31727059 DOI: 10.1186/s12913-019-4613-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
2 Clay PG, Yuet WC, Moecklinghoff CH, Duchesne I, Tronczyński KL, Shah S, Shao D. A meta-analysis comparing 48-week treatment outcomes of single and multi-tablet antiretroviral regimens for the treatment of people living with HIV. AIDS Res Ther 2018;15:17. [PMID: 30373620 DOI: 10.1186/s12981-018-0204-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
3 Taramasso L, Demma F, Bitonti R, Ferrazin A, Giannini B, Giacomini M, Beltramini S, Sasso E, Viscoli C, Di Biagio A. How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy. BMC Health Serv Res 2018;18:691. [PMID: 30189882 DOI: 10.1186/s12913-018-3507-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
4 Marcellusi A, Viti R, Russo S, Andreoni M, Antinori A, Mennini FS. Early Treatment in HIV Patients: A Cost-Utility Analysis from the Italian Perspective. Clin Drug Investig 2016;36:377-87. [PMID: 26940802 DOI: 10.1007/s40261-016-0382-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
5 Sanni-oba MB, Uthman OA, Nachega JB. Cost-effectiveness of once-daily versus twice-daily regimens in the treatment of HIV infection in sub-Saharan Africa: a probabilistic decision model. F1000Res 2016;5:2681. [DOI: 10.12688/f1000research.9954.1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Eaton EF, Tamhane A, Saag M, Mugavero MJ, Kilgore ML. Cost considerations in the current antiretroviral era. AIDS 2016;30:2115-9. [PMID: 27088319 DOI: 10.1097/QAD.0000000000001120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
7 Tse WF, Yang W, Huang W. A narrative review of cost-effectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes. Clinicoecon Outcomes Res 2015;7:431-9. [PMID: 26316787 DOI: 10.2147/CEOR.S85535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
8 Maggiolo F, Colombo GL, Di Matteo S, Bruno GM, Astuti N, Di Filippo E, Masini G, Bernardini C. Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Relat Outcome Meas 2015;6:53-60. [PMID: 25733942 DOI: 10.2147/PROM.S63586] [Cited by in F6Publishing: 2] [Reference Citation Analysis]